Timothy Rebbeck: The Future of Early Detection with Liquid Biopsy
Timothy Rebbeck/LinkedIn

Timothy Rebbeck: The Future of Early Detection with Liquid Biopsy

Timothy Rebbeck, Vincent L. Gregory, Jr. Professor of Cancer Prevention at Harvard T.H. Chan School of Public Health, and Professor at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“It’s time to take a hard look at how we approach cancer early detection with liquid biopsy tools.

  • Do we need better test performance?
  • Smarter targeting of populations?
  • Clearer definitions of what ‘success’ truly looks like?

There’s still a long way to go-but the need for effective early detection has never been greater.

Read also:

  1. Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
  2. Grail’s Cancer Detection Test Fails in Major Study.”

Other articles featuring Timothy Rebbeck on OncoDaily.